LE FLUXO DE MIXTURAS BINARI E TERTIARI DE CERA. Esseva constatate que le fluxo es un plus sensibile proprietate que le expansion thermic pro le studio del differential inter varie mixturas de cera. Le fluxo de plure lots del mesme cera revelava significative differential, indicante que un sensible test como le determination del proprietates del fluxo-debe esser usate in seliger cera pro objecti...

Stimulation of erythropoiesis by the third-generation erythropoietin drug, continuous erythropoietin receptor activator (CERA), a pegylated derivative of epoetin-beta, has provided valuable therapeutic benefits to patients suffering from renal anemia, but has also rapidly found application as an illicit performance-enhancing strategy in endurance sports. We present here a novel method for selec...

The pharmacokinetics (PK) of continuous erythropoietin receptor activator (CERA), a PEGylated erythropoietin (EPO) derivative, was studied in sheep after bone marrow (BM) busulfan ablation by using a receptor-based recirculation model and tracer interaction method (TIM) experiments. The nontracer CERA component of the TIM was analyzed using a noncompartmental approach. In contrast to EPO elimin...

(1) Continuous erythropoietin receptor activator (CERA) is a third-generation erythropoiesis stimulating agent (ESA). CERA is used to correct anemia and maintain hemoglobin levels in patients with renal (kidney) failure. CERA is administered either once every two weeks (to correct anemia) or once per month (to maintain hemoglobin levels). This offers a potential advantage over other ESAs that r...

Continuous erythropoietin receptor activator (CERA) is an erythropoietin with a long-half life. This study investigated the efficacy of CERA for correcting anemia in Korean patients on dialysis. Patients (≥ 18 yr) who were not receiving any ESAs for more than 8 weeks were randomly assigned to either intravenous CERA once every 2 weeks (n=39) or epoetin beta thrice-weekly (n=41) during a 24-week...

Background: Multifactorial anemia with chronic kidney disease (CKD) is a common problem after heart transplantation (HTX). Erythropoiesis-stimulating agents (ESAs) are commonly used to improve hemoglobin levels in patients with anemia due to CKD. With CERA (Continuous Erythropoietin Receptor Activator) a new therapeutic agent with a longer serum half time is available. However, data in patients...

OBJECTIVE The purpose of this study was to determine the cost-utility of treating anemic dialysis patients with continuous erythropoietin receptor activator (CERA) once monthly or Epoetin Beta (EpoB) thrice weekly compared with a reference strategy of managing anemia with red blood cell transfusion (RBCT). METHODS Cost-utility analysis study design. Decision analysis model, National health ca...

BACKGROUND AND OBJECTIVE We compared the hemoglobin-maintaining effects between continuous erythropoietin receptor activator (CERA) and darbepoetin-α (DA) in patients with chronic kidney disease (CKD) during the 3 months before dialysis initiation. METHODS This study was conducted with 37 CERA-administered patients and 26 DA-administered patients who had initiated dialysis at a participating ...

The present study evaluated how well auditory steady state response (ASSR) and tone burst cortical evoked response audiometry (CERA) thresholds predict behavioral thresholds in the same participants. A total of 63 ears were evaluated. For ASSR testing, 100% amplitude modulated and 10% frequency modulated tone stimuli at a modulation frequency of 40Hz were used. Behavioral thresholds were closer...